EGFR and glioblastoma: Future trials will involve an optimized rEGFRBi with the potential of enhanced T cell-mediated antitumor cytotoxicity [32], labeling of T cells to track trafficking into the GBM microenvironment, and combining EGFR BATs with other immune stimulatory agents.